Cargando…
Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis
OBJECTIVE: Despite the high efficiency of glucocorticoids (GCs), ~18–34% patients with myasthenia gravis (MG) may experience relapses of the disease. Here, we aim to identify clinical factors related to relapses during steroid tapering or after withdrawal in MG patients who were well-managed on ster...
Autores principales: | Su, Shengyao, Lei, Lin, Fan, Zhirong, Zhang, Shu, Wen, Qi, Wang, Jingsi, Lu, Yan, Di, Li, Wang, Min, Chen, Hai, Da, Yuwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854248/ https://www.ncbi.nlm.nih.gov/pubmed/35185767 http://dx.doi.org/10.3389/fneur.2022.816243 |
Ejemplares similares
-
Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020) -
Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020) -
Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022) -
Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis
por: Fan, Zhirong, et al.
Publicado: (2023) -
Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)